Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KCNH2 | Q12809 | 1/20 | 0.37 |
| ▸ | HRH3 | Q9Y5N1 | 1/20 | 0.37 |
| ▸ | GSK3B | P49841 | 2/20 | 0.32 |
| ▸ | DYRK1A | Q13627 | 2/20 | 0.32 |
| ▸ | LMNA | P02545 | 1/20 | 0.32 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.32 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.30 |
| ▸ | TP53 | P04637 | 1/20 | 0.30 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.30 |
| ▸ | TLR9 | Q9NR96 | 1/20 | 0.30 |
| ▸ | TLR8 | Q9NR97 | 1/20 | 0.30 |
| ▸ | TLR7 | Q9NYK1 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4866852 | 0.89 | KCNH2 (0.37) | KCNH2HRH3GSK3BDYRK1ALMNA | |
| SCHEMBL4872042 | 0.89 | KCNH2 (0.38) | KCNH2HRH3GSK3BDYRK1ALMNA | |
| SCHEMBL4875355 | 0.88 | KCNH2 (0.38) | KCNH2HRH3GSK3BDYRK1ALMNA | |
| SCHEMBL4877169 | 0.86 | KCNH2 (0.38) | KCNH2HRH3KMT2A | |
| SCHEMBL4871987 | 0.86 | KCNH2 (0.38) | KCNH2HRH3KMT2A | |
| SCHEMBL4877361 | 0.85 | KCNH2 (0.37) | KCNH2HRH3KMT2A | |
| SCHEMBL4866924 | 0.82 | KCNH2 (0.34) | KCNH2HRH3 | |
| SCHEMBL2989195 | 0.80 | CNR1 (0.38) | LMNAL3MBTL1KMT2A | |
| SCHEMBL4868806 | 0.79 | KCNH2 (0.36) | KCNH2HRH3LMNAKMT2ATP53 | |
| SCHEMBL4878151 | 0.79 | KCNH2 (0.38) | KCNH2HRH3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20080051384-A1 | ANTIVIRAL AGENTS | GENELABS TECHNOLOGIES, INC. | 2008-02-28 | — | — | US | disclosed |
| US-20080051384-A1 | ANTIVIRAL AGENTS | GENELABS TECHNOLOGIES, INC. | 2008-02-28 | — | — | US | disclosed |
| US-20080051384-A1 | ANTIVIRAL AGENTS | GENELABS TECHNOLOGIES, INC. | 2008-02-28 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080051384-A1 | ANTIVIRAL AGENTS | EIF2AK2, MAVS, ZC3HAV1 | KCNH2 2647/4885HRH3 4258/4885GSK3B 2798/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.